Extracellular modifications of HDL in vivo and the emerging concept of proteolytic inactivation of preβ-HDL

Current Opinion in Lipidology

Volumn 22, Issue 5, 2011, Pages 394-402

  Lee Rueckert, Miriam ^a   Kovanen, Petri T ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

Author keywords

chymase; dysfunctional HDL; HDL proteolysis; mast cells; preb HDL

Indexed keywords

ABC TRANSPORTER A1; HIGH DENSITY LIPOPROTEIN; PREBETA HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ATHEROGENESIS; ENZYME METABOLISM; GLYCOSYLATION; HUMAN; IN VIVO STUDY; LIPOLYSIS; MACROPHAGE; MAST CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

ANIMALS; ATHEROSCLEROSIS; HIGH-DENSITY LIPOPROTEINS, PRE-BETA; HUMANS; LIPOPROTEINS, HDL; PROTEOLYSIS;

EID: 80052774240     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32834a3d24     Document Type: Review

References (85)

1. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79:8-15.
2. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32:1345-1361.
3. Duffy D, Rader DJ. Update on strategies to increase HDL quantity and function. Nat Rev Cardiol 2009; 6:455-463.
4. Navab M, Reddy ST, van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011; 8:222-232.
5. Meurs I, Van EM, Van Berkel TJ. High-density lipoprotein: key molecule in cholesterol efflux and the prevention of atherosclerosis. Curr Pharm Des 2010; 16:1445-1467.
6. RothblatGH, PhillipsMC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 2010; 21:229-238.
7. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364:127-135.
8. Zhao Y, Van Berkel TJ, Van Eck M. Relative roles of various efflux pathways in net cholesterol efflux from macrophage foam cells in atherosclerotic lesions. Curr Opin Lipidol 2010; 21:441-453.
9. Barter PJ, Puranik R, Rye KA. New insights into the role of HDL as an antiinflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep 2007; 9:493-498. (Pubitemid 350081421)
10. Escola-Gil JC, Rotllan N, Julve J, Blanco-Vaca F. In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: new tools for predicting HDL atheroprotection. Atherosclerosis 2009; 206:321-327.
11. Navab M, Shechter I, Anantharamaiah GM, et al. Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol 2010; 30:164-168.
12. Thomas MJ, Bhat S, Sorci-Thomas MG. Three-dimensional models of HDL apoA-I: implications for its assembly and function. J Lipid Res 2008; 49:1875-1883.
13. Nagano Y, Arai H, Kita T. High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc Natl Acad Sci USA 1991; 88:6457-6461. (Pubitemid 21914965)
14. Bergt C, Pennathur S, Fu X, et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci USA 2004; 101:13032-13037. (Pubitemid 39167578)
15. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114:529-541. (Pubitemid 39572103)
16. Nobecourt E, Davies MJ, Brown BE, et al. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia 2007; 50:643-653. (Pubitemid 46215509)
17. Shao B, Pennathur S, Pagani I, et al. Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J Biol Chem 2010; 285: 18473-18484.
18. Pirillo A, Uboldi P, Kuhn H, Catapano AL. 15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-BI-and ABCA1-dependent cholesterol efflux from macrophages. Biochim Biophys Acta 2006; 1761: 292-300.
19. Gauster M, Oskolkova OV, Innerlohinger J, et al. Endothelial lipasemodified high-density lipoprotein exhibits diminished ability to mediate SRBI (scavenger receptor B type I)-dependent free-cholesterol efflux. Biochem J 2004; 382:75-82. (Pubitemid 39141568)
20. Ishimoto Y, Yamada K, Yamamoto S, et al. Group V and X secretory phospholipase A(2)s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions. Biochim Biophys Acta 2003; 1642:129-138. (Pubitemid 37315656)
21. Ferretti G, Bacchetti T, Marotti E, Curatola G. Effect of homocysteinylation on human high-density lipoproteins: a correlation with paraoxonase activity. Metabolism 2003; 52:146-151. (Pubitemid 36388834)
22. Cocuzzi E, Piacentini M, Beninati S, Chung SI. Posttranslational modification of apolipoprotein B by transglutaminases. Biochem J 1990; 265:707-713.
23. van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96:2758-2767.
24. Haas MJ, Mooradian AD. Regulation of high-density lipoprotein by inflammatory cytokines: establishing links between immune dysfunction and cardiovascular disease. Diabetes Metab Res Rev 2010; 26:90-99.
25. Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000; 181 (Suppl 3):S462-S472. (Pubitemid 30416122)
26. Jahangiri A, de Beer MC, Noffsinger V, et al. HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol 2009; 29:261-267.
27. Stonik JA, Remaley AT, Demosky SJ, et al. Serum amyloid A promotes ABCA1-dependent and ABCA1-independent lipid efflux from cells. Biochem Biophys Res Commun 2004; 321:936-941. (Pubitemid 39044399)
28. Nobecourt E, Tabet F, Lambert G, et al. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2010; 30:766-772.
29. Asleh R, Miller-Lotan R, AviramM, et al. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ Res 2006; 99:1419-1425. (Pubitemid 44949678)
30. Kunitake ST, Chen GC, Kung SF, et al. Prebeta high-density lipoprotein. Unique disposition of apolipoprotein A-I increases susceptibility to proteolysis. Arteriosclerosis 1990; 10:25-30. (Pubitemid 20035101)
31. Miida T, Kawano M, Fielding CJ, Fielding PE. Regulation of the concentration of prebeta high density lipoprotein in normal plasma by cell membranes and lecithin-cholesterol acyltransferase activity. Biochemistry 1992; 31:11112-11117.
32. Olin KL, Potter-Perigo S, Barrett PH, et al. Biglycan, a vascular proteoglycan, binds differently to HDL2 and HDL3: role of apoE. Arterioscler Thromb Vasc Biol 2001; 21:129-135. (Pubitemid 32061937)
33. Eberini I, Gianazza E, Breghi L, et al. Apolipoprotein A-I breakdown is induced by thrombolysis in coronary patients. Ann Med 2007; 39:306-311. (Pubitemid 46897663)
34. Ndao M, Spithill TW, Caffrey R, et al. Identification of novel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profiling. J Clin Microbiol 2010; 48:1139-1149.
35. Judstrom I, Jukkola H, Metso J, et al. Mast cell-dependent proteolytic modification of HDL particles during anaphylactic shock in the mouse reduces their ability to induce cholesterol efflux from macrophage foam cells ex vivo. Atherosclerosis 2010; 208:148-154.
36. LizMA, Faro CJ, Saraiva MJ, Sousa MM. Transthyretin, a new cryptic protease. J Biol Chem 2004; 279:21431-21438. (Pubitemid 38656553)
37. Liz MA, Gomes CM, Saraiva MJ, Sousa MM. ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. J Lipid Res 2007; 48:2385-2395. (Pubitemid 350058750)
38. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 2006; 113:2548-2555. (Pubitemid 43948034)
39. Duong PT, Weibel GL, Lund-Katz S, et al. Characterization and properties of pre beta-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I. J Lipid Res 2008; 49:1006-1014.
40. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010; 30:796-801.
41. Bashtovyy D, Jones MK, Anantharamaiah GM, Segrest JP. Sequence conservation of apolipoprotein A-I affords novel insights into HDL structurefunction. J Lipid Res 2011; 52:435-450.
42. Holzer M, Gauster M, Pfeifer T, et al. Protein carbamylation renders highdensity lipoprotein dysfunctional. Antioxid Redox Signal 2011.
43. Pirillo A, Uboldi P, Pappalardo G, et al. Modification of HDL3 by mild oxidative stress increases ATP-binding cassette transporter 1-mediated cholesterol efflux. Cardiovasc Res 2007; 75:566-574. (Pubitemid 47080967)
44. Pirillo A, Uboldi P, Catapano AL. Dual effect of hypochlorite in the modification of high density lipoproteins. Biochem Biophys Res Commun 2010; 403: 447-451.
45. Gao X, Jayaraman S, Gursky O. Mild oxidation promotes and advanced oxidation impairs remodeling of human high-density lipoprotein in vitro. J Mol Biol 2008; 376:997-1007.
46. Cavigiolio G, Geier EG, Shao B, et al. Exchange of apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high-density lipoproteins. J Biol Chem 2010; 285:18847-18857.
47. Lee M, von Eckardstein A, Lindstedt L, et al. Depletion of preb1LpA1 and LpA4 particles by mast cell chymase reduces cholesterol efflux from macrophage foam cells induced by plasma. Arterioscler Thromb Vasc Biol 1999; 19:1066-1074. (Pubitemid 29177357)
48. Lee-Rueckert M, vonEckardstein A, Kovanen PT. The neutral protease chymase degrades apolipoprotein E from high-density lipoproteins. Clin Chem Lab Med 2008; 46:421-423. (Pubitemid 351317772)
49. Lee M, Kovanen PT, Tedeschi G, et al. Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux. J Lipid Res 2003; 44:539-546. (Pubitemid 37279702)
50. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into preb-migrating high density lipoprotein. Biochemistry 1988; 27:25-29. (Pubitemid 18036281)
51. Lindstedt L, Saarinen J, Kalkkinen N, et al. Matrix metalloproteinases-3, -7, and-12, but not-9, reduce high-density lipoprotein-induced cholesterol efflux from human macrophage foam cells by truncation of the carboxyl terminus of apolipoprotein A-I. Parallel losses of prebeta particles and the high affinity component of efflux. J Biol Chem 1999; 274:22627-22634.
52. Eberini I, Calabresi L, Wait R, et al. Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N-and Ctermini. Biochem J 2002; 362:627-634. (Pubitemid 34242313)
53. Lindstedt L, Kovanen PT. Plasmin and kallikrein reduce HDL-induced cholesterol efflux from foam cells. Biochem Biophys Res Commun 2000; 277:552-557.
54. Lindstedt L, Lee M, Oorni K, et al. Cathepsins F and S block HDL3-induced cholesterol efflux from macrophage foam cells. Biochem Biophys Res Commun 2003; 312:1019-1024. (Pubitemid 37490917)
55. Cogny A, Atger V, Paul J-L, et al. High-density lipoprotein 3 physicochemical modifications induced by interaction with human polymorphonuclear leucocytes affect their ability to remove cholesterol from cells. Biochem J 1996; 314:285-292. (Pubitemid 26063860)
56. Kaartinen M, Penttilä A, Kovanen PT. Mast cells of two types differing in neutral protease composition in the human aortic intima. Arterioscler Thromb 1994; 14:966-972.
57. Lee M, Sommerhoff CP, von Eckardstein A, et al. Mast cell tryptase degrades HDL and blocks its function as an acceptor of cellular cholesterol. Arterioscler Thromb Vasc Biol 2002; 22:2086-2091. (Pubitemid 36025219)
58. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94:2493-2503. (Pubitemid 24379627)
59. Oorni K, Sneck M, Bromme D, et al. Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro. J Biol Chem 2004; 279:34776-34784. (Pubitemid 39318110)
60. Sukhova GK, Shi GP, Simon DI, et al. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998; 102:576-583. (Pubitemid 28376160)
61. Lee M, Lindstedt L, Kovanen PT. Mast cell-mediated inhibition of reverse cholesterol transport. Arterioscler Thromb 1992; 12:1329-1335.
62. Cerf M, Raidoo D, Fink E, et al. Plasma kallikrein localisation in human blood vessels. Immunopharmacology 1999; 44:75-80.
63. Dollery CM, Owen CA, Sukhova GK, et al. Neutrophil elastase in human atherosclerotic plaques, production by macrophages. Circulation 2003; 107:2829-2836. (Pubitemid 36705994)
64. Grainger DJ, Kemp PR, Liu AC, et al. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994; 370:460-462. (Pubitemid 24263550)
65. Lee-Rueckert M, Kovanen PT. Mast cell proteases: physiological tools to study functional significance of high density lipoproteins in the initiation of reverse cholesterol transport. Atherosclerosis 2006; 189:8-18. (Pubitemid 44441294)
66. Pejler G, Ronnberg E, Waern I, Wernersson S. Mast cell proteases: multifaceted regulators of inflammatory disease. Blood 2010; 115:4981-4990.
67. Lee-Rueckert M, Lappalainen J, Leinonen H, et al. Acidic extracellular environments strongly impair ABCA1-mediated cholesterol efflux from human macrophage foam cells. Arterioscler Thromb Vasc Biol 2010; 30:1766-1772.
68. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 1995; 92:1084-1088.
69. Libby P, Shi GP. Mast cells as mediators and modulators of atherogenesis. Circulation 2007; 115:2471-2473. (Pubitemid 46763219)
70. Kovanen PT. Mast cells in human fatty streaks and atheromas: Implications for intimal lipid accumulation. Curr Opin Lipidol 1996; 7:281-286. (Pubitemid 26372446)
71. Lindstedt L, Lee M, Kovanen PT. Chymase bound to heparin is resistant to its natural inhibitors and capable of proteolyzing high-density lipoproteins in aortic intimal fluid. Atherosclerosis 2001; 155:87-97. (Pubitemid 32167128)
72. Lindstedt L, Lee M, Castro GR, et al. Chymase in exocytosed rat mast cell granules effectively proteolyzes apolipoprotein AI-containing lipoproteins, so reducing the cholesterol efflux-inducing ability of serum and aortic intimal fluid. J Clin Invest 1996; 97:2174-2182. (Pubitemid 26165707)
73. Lee M, Uboldi P, Giudice D, et al. Identification of domains in apoA-I susceptible to proteolysis by mast cell chymase. Implications for HDL function. J Lipid Res 2000; 41:975-984. (Pubitemid 30434329)
74. Lee-Rueckert M, Vikstedt R, Metso J, et al. Association of cholesteryl ester transfer protein with HDL particles reduces its proteolytic inactivation by mast cell chymase. J Lipid Res 2008; 49:358-368. (Pubitemid 351213620)
75. Favari E, Lee M, Calabresi L, et al. Depletion of prebeta-HDL by human chymase impairs ATP-binding cassette transporter A1-but not SR-B1-mediated lipid efflux to HDL. J Biol Chem 2004; 279:9930-9936.
76. Chantepie S, Malle E, Sattler W, et al. Distinct HDL subclasses present similar intrinsic susceptibility to oxidation by HOCl. Arch Biochem Biophys 2009; 487:28-35.
77. Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient prebeta-HDL formation and increases reverse cholesterol transport. J Lipid Res 2010; 51:3443-3454.
78. Rader DJ, Alexander ET, Weibel GL, et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009; 50 (Suppl):S189-S194.
79. Lee-Rueckert M, Silvennoinen R, Rotllan N, et al. Mast cell activation in vivo impairs the macrophage reverse cholesterol transport pathway in the mouse. Arterioscler Thromb Vasc Biol 2011; 31:520-527.
80. Westermark P, Mucchiano G, Marthin T, et al. Apolipoprotein AI-derived amyloid in human aortic atherosclerotic plaques. Am J Pathol 1995; 147: 1186-1192.
81. Niemi K, Baumann MH, Kovanen PT, Eklund KK. Serum amyloid A (SAA) activates human mast cells, which leads into degradation of SAA and generation of an amyloidogenic SAA fragment. Biochim Biophys Acta 2006; 1762:424-430. (Pubitemid 43344303)
82. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117:746-756. (Pubitemid 46348533)
83. Davidsson P, Hulthe J, Fagerberg B, Camejo G. Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler Thromb Vasc Biol 2010; 30:156-163.
84. Gordon SM, Deng J, Lu LJ, Davidson WS. Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J Proteome Res 2010; 9:5239-5249.
85. Ortiz-Munoz G, Houard X, Martin-Ventura JL, et al. HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. FASEB J 2009; 23:3129-3139.